Strata Skin科學 SSKN 深 滬
等待開盤 10-02 09:30:00 美东时间
2.10
+0.040
+1.94%
華盛通- 最 高2.16
- 今 開2.06
- 成交量 12.07万股
- 最 低 2.04
- 昨 收 2.06
- 總市值 1106.43万
- 52周最高 3.86
- 市盈率 靜 --
- 換手率 2.29%
- 52周最低 1.38
- 委 比 -96.23%
- 總股本 526.87万
- 歷史最高 3480.00
- 量 比 0.18
- 振 幅 5.83%
- 歷史最低 1.38
- 每 手 1
- 風險率 1.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Strata Skin's Treatment For Plaque-Type Psoriasis Enhances Outcomes Compared To Topical Monotherapy, Study Demonstrates
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative
09-30 20:21
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
A study published in Lasers in Medical Science highlights that STRATA Skin Sciences' XTRAC 308nm Excimer Laser, when combined with 0.1% tacrolimus ointment, significantly improves outcomes for plaque-type psoriasis patients compared to topical monotherapy. The randomized study of 100 patients showed a 74% PASI reduction with the combination therapy versus 70% with monotherapy, with no serious adverse events. The findings demonstrate the effective...
09-30 12:15
3 Penny Stocks to Watch Now, 9/25/25
Datavault AI, Strata Skin Sciences, and Soluna Holdings are the 3Penny St...
09-25 23:02
STRATA Skin Sciences Highlights Peer-Reviewed Study Showing Superior Efficacy Of 308nm Excimer Laser In Combination With Oral JAK Inhibitor In Vitiligo Treatment
STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions,
09-22 20:22
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach
A study published in the *International Journal of Dermatology* highlights the superior efficacy and safety of combining STRATA's 308nm Excimer laser with a JAK inhibitor for treating localized vitiligo. The randomized controlled trial, involving 251 patients, demonstrated a 14.20% higher repigmentation rate, 100% efficacy, 96.5% pigmentation stability, and no serious adverse events. This confirms the combination therapy's advantages over monothe...
09-22 12:15
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements
STRATA Skin Sciences introduces its Elevate 360 consulting platform, designed to optimize partner clinics' revenue through best practices in marketing, reimbursement, and patient retention. Since launching in early 2025, the program has driven a 7% year-over-year growth for participating clinics. A notable success involves a partner expanding from two to nine clinics, increasing revenue from $10,500 to $61,800 in six months. STRATA plans to lever...
09-04 12:15
Strata Skin Sciences Raises $2.4M in Stock Offering
Strata Skin Sciences ( ($SSKN) ) has shared an update. On September 2, 2025, St...
09-03 20:48
STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules
STRATA Skin Sciences, Inc. has entered into definitive agreements with institutional investors to sell 1,097,547 shares of common stock at $2.204 per share through a registered direct offering under Nasdaq rules. The offering is priced at-market and expected to close on September 4, 2025, subject to customary conditions. Gross proceeds to the Company are approximately $2.42 million, with net proceeds intended for working capital and general corpo...
09-03 12:00
Strata Skin Sciences shares are trading higher after the company announced that its patent portfolio provides intellectual property and market exclusivity for combination therapies of its XTRAC excimer laser when used with JAK inhibitor
Strata Skin Sciences shares are trading higher after the company announced that...
09-02 21:26
STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
STRATA Skin Sciences, Inc. announced that its CEO, Dr. Dolev Rafaeli, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, at the Lotte New York Palace Hotel. The presentation will be available on demand starting September 5, 2025, at 7:00am ET for registered investors. Strata Skin Sciences specializes in innovative dermatologic treatments, offering products like the XTRAC® exc...
09-02 20:05
